


29 / BIOLOGY AND REPAIR

What Comes After the Daily Pill?

RNA medicines, PCSK9, and the distinction between changing cholesterol and proving an outcome.

JOHN GRIFFIN, MD

REVIEW EDITION · OCTOBER 2026

Change the instruction, change the schedule

Some medicines act on proteins already present. RNA-based approaches can alter the production of a protein. That difference creates opportunities for longer-lasting effects, but duration alone does not establish a better clinical choice.

Inclisiran provides a specific example. It is a small interfering RNA directed at hepatic production of PCSK9. It should not be confused with mRNA vaccines or permanent DNA editing simply because each belongs to a discussion of genetic information.

What the pivotal comparison measured

ORION-10 and ORION-11 randomized patients with elevated LDL cholesterol despite maximally tolerated statin therapy. Their main endpoints were changes in LDL cholesterol. The trials reported placebo-corrected reductions of approximately 50%, with injection-site events more frequent in the inclisiran groups and generally mild. [1]

Those are meaningful lipid findings. The trials were not, by that endpoint alone, proof of a particular reduction in heart attacks or deaths. An outcome claim needs the outcome evidence, not a transfer of the same percentage from cholesterol to events.

Convenience is part of effectiveness

A less frequent treatment schedule can be attractive. Whether it helps a particular person depends on access, follow-up, tolerance, cost, and the treatment alternatives. A missed appointment is a different adherence problem from a missed tablet, not the disappearance of adherence as a concern.

Long duration also makes reversibility worth discussing. Readers should ask how long an effect lasts, what monitoring is required, and what can be done if a problem occurs.

Keep the technologies separate

Antibodies against PCSK9, RNA interference, and gene-editing strategies can share a target while having different exposure, persistence, evidence, and risks. One successful approach does not validate the others.

This booklet uses the original lipid trials to explain that distinction. It is not a current prescribing guide or a complete review of later outcome evidence. The next useful question is which intervention has demonstrated which benefit, in whom, at what burden. A future with fewer pills will be better when it also produces better outcomes people can depend on.

SOURCES & READING SCOPE

Keep the claim beside its evidence

1. Kausik K Ray, R Scott Wright, David Kallend, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. The New England journal of medicine. 2020 Apr 16;382(16):1507-1519. doi:10.1056/NEJMoa1912387. PMID:32187462. Open source →

Selected primary publication records and abstracts checked 25–26 October 2026. This is a focused reading companion, not a systematic review, a treatment protocol, or a complete appraisal of methods, supplements and later evidence.

KEEP FOLLOWING THE IDEA

Part of a connected collection

Return to a subject, follow a related booklet, or explore the wider projects. These links organize reading; they do not imply that one scientific finding proves another.

This booklet online →

Booklet directory · all 48 →

Atlas · PCSK9 inhibitors (antibodies, inclisiran) →

Arising Health website →

The Arising book →

The Long Game →

Listen & watch →

Related booklets

18 · The Protection of Ordinary Days →

07 · Editing the Code →

06 · When Medicines Become Instructions →

The online review collection is hosted in the shared Atlas. Its existing access settings apply. The public website remains a separate destination.